Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$489.10 3.21 (0.66%) as of 4:30 Thu 4/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 127.19(B)
Last Volume: 1,205,470 Avg Vol: 1,557,383
52 Week Range: $392.81 - $516.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  180
Guru Rank Value     : 7.8
Guru Occurances    : 3

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 39,145 57,358 158,483 419,993
Total Sell Value $18,922,852 $28,311,810 $76,426,554 $176,964,417
Total People Sold 6 7 13 15
Total Sell Transactions 21 24 50 119
End Date 2025-01-16 2024-10-15 2024-04-16 2023-04-17

   
Records found: 1660
  Page 1 of 67  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Altshuler David EVP, Chief Scientific Officer   •       –      –    2025-03-13 4 AS $510.00 $1,647,810 D/D (3,231) 23,281 -4%     
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2025-03-10 4 AS $500.00 $1,649,000 D/D (3,298) 51,671 -3%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2025-03-10 4 AS $499.99 $1,620,968 D/D (3,242) 51,239 -3%     
   Altshuler David EVP, Chief Scientific Officer   •       –      –    2025-03-10 4 AS $500.00 $1,615,500 D/D (3,231) 26,512 -3%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2025-03-04 4 AS $485.49 $1,970,118 D/D (4,058) 54,481 -0%     
   Altshuler David EVP, Chief Scientific Officer   •       –      –    2025-03-03 4 AS $490.00 $1,583,190 D/D (3,231) 29,743 0%     
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2025-02-27 4 AS $475.34 $1,259,651 D/D (2,650) 19,352 2%     
   Altshuler David EVP, Chief Scientific Officer   •       –      –    2025-02-27 4 AS $480.00 $610,560 D/D (1,272) 32,974 2%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2025-02-27 4 AS $475.34 $251,930 D/D (530) 58,539 2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2025-02-26 4 D $479.61 $3,391,322 D/D (7,071) 62,935     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2025-02-26 4 D $479.61 $1,190,392 D/D (2,482) 22,002     -
   Altshuler David EVP, Chief Scientific Officer   •       –      –    2025-02-26 4 D $479.61 $2,855,598 D/D (5,954) 34,246     -
   Kewalramani Reshma CEO & President   •       •      –    2025-02-26 4 D $479.61 $6,752,429 D/D (14,079) 105,915     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2025-02-26 4 D $479.61 $2,379,825 D/D (4,962) 54,969     -
   Bozic Carmen EVP and CMO   •       –      –    2025-02-26 4 D $479.61 $2,379,825 D/D (4,962) 32,669     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2025-02-26 4 D $479.61 $2,379,825 D/D (4,962) 59,069     -
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2025-02-26 4 D $479.61 $1,775,996 D/D (3,703) 68,490     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2025-02-26 4 D $479.61 $595,196 D/D (1,241) 7,845     -
   Altshuler David EVP, Chief Scientific Officer   •       –      –    2025-02-25 4 AS $480.95 $407,846 D/D (848) 40,200 1%     
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2025-02-25 4 AS $480.95 $425,160 D/D (884) 9,086 1%     
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2025-02-25 4 AS $480.95 $849,839 D/D (1,767) 24,484 1%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2025-02-25 4 AS $480.95 $170,256 D/D (354) 64,031 1%     
   Arbuckle Stuart A EVP, COO   •       –      –    2025-02-24 4 D $483.28 $2,279,148 D/D (4,716) 70,006     -
   Altshuler David EVP, Chief Scientific Officer   •       –      –    2025-02-24 4 D $483.28 $1,919,105 D/D (3,971) 41,048     -
   Bozic Carmen EVP and CMO   •       –      –    2025-02-24 4 D $483.28 $1,599,657 D/D (3,310) 37,631     -
  1660 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 67
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us